10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2022 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2022 10-K (Filed: Feb 14, 2023) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2022 | Dec 31, 2021 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 9,123 | 13,979 |
| Marketable debt securities | 130 | 2,987 |
| Receivables | 9,886 | 9,369 |
| Inventories | 2,339 | 2,095 |
| Other current assets | 5,795 | 4,832 |
| Total Current Assets | 27,273 | 33,262 |
| Property, plant and equipment | 6,255 | 6,049 |
| Goodwill | 21,149 | 20,502 |
| Other intangible assets | 35,859 | 42,527 |
| Deferred income taxes | 1,344 | 1,439 |
| Other non-current assets | 4,940 | 5,535 |
| Total Assets | 96,820 | 109,314 |
| LIABILITIES | ||
| Current Liabilities: | ||
| Short-term debt obligations | 4,264 | 4,948 |
| Accounts payable | 3,040 | 2,949 |
| Other current liabilities | 14,586 | 13,971 |
| Total Current Liabilities | 21,890 | 21,868 |
| Deferred income taxes | 2,166 | 4,501 |
| Long-term debt | 35,056 | 39,605 |
| Other non-current liabilities | 6,590 | 7,334 |
| Total Liabilities | 65,702 | 73,308 |
| Commitments and contingencies | ||
| EQUITY | ||
| Bristol-Myers Squibb Company Shareholders Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 2,991 in 2022 and 3,484 in 2021, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2022 and 2021 | 292 | 292 |
| Capital in excess of par value of stock | 45,165 | 44,361 |
| Accumulated other comprehensive loss | (1,281) | (1,268) |
| Retained earnings | 25,503 | 23,820 |
| Less cost of treasury stock 825 million common shares in 2022 and 747 million common shares in 2021 | (38,618) | (31,259) |
| Total Bristol-Myers Squibb Company Shareholders Equity | 31,061 | 35,946 |
| Noncontrolling interest | 57 | 60 |
| Total Equity | 31,118 | 36,006 |
| Total Liabilities and Equity | 96,820 | 109,314 |
| External Links | |
| BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2022 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |